Clinical Trials Arena on MSN3d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint
BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...
Managed Healthcare Executive2d
Trial Supports Bizengri as a Promising Treatment for NRG1 Fusion-Positive Cancers, Including Advanced Lung Cancer
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...
Targeted Oncology19h
Phase 3 Trial Evaluates SC Pembrolizumab vs IV in NSCLC
Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.
Clinical Trials Arena on MSN3d
Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia
Irish biopharmaceutical company Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 ...
Targeted Oncology1d
Behind Durvalumab's FDA Approval: NIAGARA Trial in MIBC
Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...
CURE2d
Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial
Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...
Greenwich LifeSciences announces ‘positive’ data from FLAMINGO-01 trial
Greenwich LifeSciences (GLSI) announced the following update on FLAMINGO-01 open label immune response data. The company has analyzed the ...
The Lancet5d
Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial
The data presented support use of MR vaccine at 6 months to protect young infants during measles outbreaks and in settings ...
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Seeking Alpha9d
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients ...
Edgewise Therapeutics’ EDG-7500 Shows Promise in Phase 2 Trial for Hypertrophic Cardiomyopathy
The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...